Cronos (CRON) 10-Q 8 Aug 24 2024 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2024	Aug. 05, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-38403
Entity Registrant Name	CRONOS GROUP INC.
Entity Incorporation, State or Country Code	Z4
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	4491 Concession Rd 12
Entity Address, City or Town	Stayner
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	L0M 1S0
City Area Code	416
Local Phone Number	504-0004
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	CRON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		382,280,725
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001656472
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 848,189	$ 669,291
Short-term investments	0	192,237
Accounts receivable, net	16,179	13,984
Interest receivable	5,183	10,012
Other receivables	7,227	6,341
Current portion of loans receivable, net	4,875	5,541
Inventory, net	29,182	30,495
Prepaids and other current assets	5,246	5,405
Held-for-sale assets	19,197	0
Total current assets	935,278	933,306
Equity method investments, net	21,226	19,488
Other investments	3,168	35,251
Non-current portion of loans receivable, net	73,165	69,036
Property, plant and equipment, net	36,964	59,468
Right-of-use assets	1,079	1,356
Goodwill	1,024	1,057
Intangible assets, net	19,103	21,078
Other assets	41	45
Total assets	1,091,048	1,140,085
Current liabilities
Accounts payable	7,840	12,130
Income taxes payable	61	64
Accrued liabilities	23,846	27,736
Current portion of lease obligation	931	994
Derivative liabilities	21	102
Current portion due to non-controlling interests	358	373
Total current liabilities	33,057	41,399
Non-current portion due to non-controlling interests	1,137	1,003
Non-current portion of lease obligation	1,062	1,559
Total liabilities	35,256	43,961
Shareholders’ equity
Share capital (authorized for issue as of June 30, 2024 and December 31, 2023: unlimited; shares outstanding as of June 30, 2024 and December 31, 2023: 382,280,725 and 381,298,853, respectively)	616,379	613,725
Additional paid-in capital	49,298	48,449
Retained earnings	405,650	416,719
Accumulated other comprehensive gain (loss)	(12,013)	20,678
Total equity attributable to shareholders of Cronos Group	1,059,314	1,099,571
Non-controlling interests	(3,522)	(3,447)
Total shareholders’ equity	1,055,792	1,096,124
Total liabilities and shareholders’ equity	$ 1,091,048	$ 1,140,085

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	382,280,725	381,298,853
Common stock, shares outstanding (in shares)	382,280,725	381,298,853

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net revenue, before excise taxes	$ 38,678	$ 25,798	$ 74,045	$ 52,352
Excise taxes	(10,916)	(6,777)	(20,995)	(13,836)
Net revenue	27,762	19,021	53,050	38,516
Cost of sales	21,070	15,922	41,875	32,490
Inventory write-down	395	0	395	0
Gross profit	6,297	3,099	10,780	6,026
Operating expenses
Sales and marketing	4,330	5,297	9,662	11,038
Research and development	962	1,107	1,959	3,146
General and administrative	12,767	13,451	21,674	25,307
Restructuring costs	547	0	630	0
Share-based compensation	2,236	2,331	4,251	4,866
Depreciation and amortization	1,016	1,533	2,139	3,058
Impairment loss on long-lived assets	0	0	1,974	0
Total operating expenses	21,858	23,719	42,289	47,415
Operating loss	(15,561)	(20,620)	(31,509)	(41,389)
Other income
Interest income, net	13,451	12,471	27,696	23,646
Share of income (loss) from equity method investments	917	270	2,365	(226)
Gain (loss) on revaluation of financial instruments	(3,615)	5,193	(6,257)	(2,565)
Impairment loss on other investments	(12,916)	0	(25,650)	0
Foreign currency transaction gain (loss)	6,543	(3,174)	19,802	(4,817)
Other, net	248	17	(422)	37
Total other income	4,628	14,777	17,534	16,075
Loss before income taxes	(10,933)	(5,843)	(13,975)	(25,314)
Income tax benefit	(2,174)	(180)	(2,732)	(1,616)
Loss from continuing operations	(8,759)	(5,663)	(11,243)	(23,698)
Loss from discontinued operations	0	(2,834)	0	(4,056)
Net loss	(8,759)	(8,497)	(11,243)	(27,754)
Net loss attributable to non-controlling interest	(2)	(137)	(245)	(225)
Net loss attributable to Cronos Group	(8,757)	(8,360)	(10,998)	(27,529)
Comprehensive income (loss)
Net loss	(8,759)	(8,497)	(11,243)	(27,754)
Other comprehensive income (loss)
Foreign exchange gain (loss) on translation	(10,160)	16,580	(32,521)	18,994
Comprehensive income (loss)	(18,919)	8,083	(43,764)	(8,760)
Comprehensive income (loss) attributable to non-controlling interests	58	(87)	(75)	(95)
Comprehensive income (loss) attributable to Cronos Group	$ (18,977)	$ 8,170	$ (43,689)	$ (8,665)
Net loss per share
Basic - continuing operations (in dollars per share)	$ (0.02)	$ (0.01)	$ (0.03)	$ (0.06)
Diluted - continuing operations (in dollars per share)	(0.02)	(0.01)	(0.03)	(0.06)
Basic - discontinued operations (in dollars per share)	0	(0.01)	0	(0.01)
Diluted - discontinued operations (in dollars per share)	0	(0.01)	0	(0.01)
Basic - total (in dollars per share)	(0.02)	(0.02)	(0.03)	(0.07)
Diluted - total (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.03)	$ (0.07)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Share capital	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non-controlling interests
Beginning balance (in shares) at Dec. 31, 2022		380,575,403
Beginning balance at Dec. 31, 2022	$ 1,140,964	$ 611,318	$ 42,682	$ 490,682	$ (797)	$ (2,921)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		240,518
Activities relating to share-based compensation	2,279	$ 917	1,362
Net loss	(19,257)			(19,169)		(88)
Foreign exchange gain (loss) on translation	2,414				2,334	80
Ending balance (in shares) at Mar. 31, 2023		380,815,921
Ending balance at Mar. 31, 2023	1,126,400	$ 612,235	44,044	471,513	1,537	(2,929)
Beginning balance (in shares) at Dec. 31, 2022		380,575,403
Beginning balance at Dec. 31, 2022	1,140,964	$ 611,318	42,682	490,682	(797)	(2,921)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(27,754)
Foreign exchange gain (loss) on translation	18,994
Ending balance (in shares) at Jun. 30, 2023		381,089,357
Ending balance at Jun. 30, 2023	1,136,673	$ 613,152	45,317	463,153	18,067	(3,016)
Beginning balance (in shares) at Mar. 31, 2023		380,815,921
Beginning balance at Mar. 31, 2023	1,126,400	$ 612,235	44,044	471,513	1,537	(2,929)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		273,436
Activities relating to share-based compensation	2,190	$ 917	1,273
Net loss	(8,497)			(8,360)		(137)
Foreign exchange gain (loss) on translation	16,580				16,530	50
Ending balance (in shares) at Jun. 30, 2023		381,089,357
Ending balance at Jun. 30, 2023	$ 1,136,673	$ 613,152	45,317	463,153	18,067	(3,016)
Beginning balance (in shares) at Dec. 31, 2023	381,298,853	381,298,853
Beginning balance at Dec. 31, 2023	$ 1,096,124	$ 613,725	48,449	416,719	20,678	(3,447)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		712,325
Activities relating to share-based compensation	1,499	$ 1,900	(401)
Net loss	(2,484)			(2,241)		(243)
Foreign exchange gain (loss) on translation	(22,361)				(22,471)	110
Ending balance (in shares) at Mar. 31, 2024		382,011,178
Ending balance at Mar. 31, 2024	$ 1,072,778	$ 615,625	48,048	414,478	(1,793)	(3,580)
Beginning balance (in shares) at Dec. 31, 2023	381,298,853	381,298,853
Beginning balance at Dec. 31, 2023	$ 1,096,124	$ 613,725	48,449	416,719	20,678	(3,447)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(11,243)
Foreign exchange gain (loss) on translation	$ (32,521)
Ending balance (in shares) at Jun. 30, 2024	382,280,725	382,280,725
Ending balance at Jun. 30, 2024	$ 1,055,792	$ 616,379	49,298	405,650	(12,013)	(3,522)
Beginning balance (in shares) at Mar. 31, 2024		382,011,178
Beginning balance at Mar. 31, 2024	1,072,778	$ 615,625	48,048	414,478	(1,793)	(3,580)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		269,547
Activities relating to share-based compensation	1,933	$ 754	1,250	(71)
Net loss	(8,759)			(8,757)		(2)
Foreign exchange gain (loss) on translation	$ (10,160)				(10,220)	60
Ending balance (in shares) at Jun. 30, 2024	382,280,725	382,280,725
Ending balance at Jun. 30, 2024	$ 1,055,792	$ 616,379	$ 49,298	$ 405,650	$ (12,013)	$ (3,522)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Operating activities
Net loss	$ (8,759)	$ (2,484)	$ (8,497)	$ (19,257)	$ (11,243)	$ (27,754)
Adjustments to reconcile net loss to cash used in operating activities:
Share-based compensation					4,251	4,887
Depreciation and amortization					3,244	4,785
Impairment loss on long-lived assets					1,974	205
Impairment loss on other investments	12,916		0		25,650	0
Loss from investments					3,732	2,955
Changes in expected credit losses on long-term financial assets					1,021	(1,146)
Foreign currency transaction (gain) loss	(6,543)		3,174		(19,802)	4,817
Other non-cash operating activities, net					829	(554)
Changes in operating assets and liabilities:
Accounts receivable, net					(2,723)	10,623
Interest receivable					1,174	(10,243)
Other receivables					(1,009)	(200)
Prepaids and other current assets					(5)	480
Inventory					292	(7,259)
Accounts payable					(4,482)	(2,478)
Income taxes payable					(47)	(32,801)
Accrued liabilities					(3,316)	(5,784)
Cash flows used in operating activities					(460)	(59,467)
Investing activities
Purchase of short-term investments					0	(479,763)
Proceeds from short-term investments					187,447	169,418
Dividends received from equity method investment					0	1,299
Advances on loans receivable					(8,836)	0
Proceeds from repayment on loans receivable					5,298	11,388
Purchase of property, plant and equipment					(2,453)	(1,298)
Purchase of intangible assets					(457)	(8)
Cash flows provided by (used in) investing activities					180,999	(298,964)
Financing activities
Withholding taxes paid on share-based awards					(905)	(782)
Cash flows used in financing activities					(905)	(782)
Effect of foreign currency translation on cash and cash equivalents					(736)	3,997
Net change in cash and cash equivalents					178,898	(355,216)
Cash and cash equivalents, beginning of period		$ 669,291		$ 764,644	669,291	764,644	$ 764,644
Cash and cash equivalents, end of period	$ 848,189		$ 409,428		848,189	409,428	$ 669,291
Supplemental cash flow information
Interest paid					0	0
Interest received					28,291	13,385
Income taxes paid					$ 614	$ 32,995

Background, Basis of Presentati

Background, Basis of Presentation, and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background, Basis of Presentation, and Summary of Significant Accounting Policies	Background, Basis of Presentation, and Summary of Significant Accounting Policies (a) Background Cronos Group Inc. (“Cronos” or the “Company”) is incorporated in the province of British Columbia under the Business Corporations Act (British Columbia) with principal executive offices at 4491 Concession Rd 12, Stayner, Ontario, L0M 1S0. The Company’s common shares are listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.” Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach ® , PEACE NATURALS ® and Lord Jones ® . (b) Basis of presentation These condensed consolidated interim financial statements of Cronos are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”). Certain prior period amounts have been reclassified to conform to the current year presentation of our condensed consolidated interim financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity. (c) Discontinued Operations In the second quarter of 2023, the Company exited its U.S. hemp-derived cannabinoid product operations. The exit of the U.S. operations represented a strategic shift that had a major effect on the Company’s operations and financial results, and as such, qualifies for reporting as discontinued operations in our condensed consolidated statements of net loss and comprehensive income (loss). Prior period amounts have been reclassified to reflect the discontinued operations classification of the U.S. operations. For more information, see Note 2 “ Discontinued Operations. ” (d) Segment information Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. Prior to the second quarter of 2023, the Company reported results for two reportable segments, the U.S. and Rest of World. In the second quarter of 2023, as a result of the Company’s exit of its then-existing U.S. operations, the Company determined that it has one operating segment and therefore one reportable segment, which is comprised of operations in Canada and Israel and is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets . All prior period segment disclosure information has been reclassified to conform to the current reporting structure in this Form 10-Q. These reclassifications had no effect on our consolidated financial statements in any period presented. (e) Revenue recognition The following tables present the Company’s revenue by major product category for continuing operations: Three months ended June 30, 2024 2023 Cannabis flower $ 20,661 $ 14,014 Cannabis extracts 7,064 4,926 Other 37 81 Net revenue $ 27,762 $ 19,021 Six months ended June 30, 2024 2023 Cannabis flower $ 38,186 $ 27,142 Cannabis extracts 14,791 11,227 Other 73 147 Net revenue $ 53,050 $ 38,516 Net revenue attributed to a geographic region based on the location of the customer were as follows for continuing operations: Three months ended June 30, 2024 2023 Canada $ 19,844 $ 13,595 Israel 6,889 5,426 Other countries 1,029 — Net revenue $ 27,762 $ 19,021 Six months ended June 30, 2024 2023 Canada $ 38,715 $ 28,029 Israel 13,306 10,487 Other countries 1,029 — Net revenue $ 53,050 $ 38,516 (f) Concentration of risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments and loans receivable. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $954,818 and $966,442 as of June 30, 2024 and December 31, 2023, respectively. An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of June 30, 2024 and December 31, 2023, the Company had $20 and $3, respectively, in expected credit losses that have been recognized on receivables from contracts with customers. As of June 30, 2024, the Company assessed that there is a concentration of credit risk, as 30% of the Company’s accounts receivable were due from one customer with an established credit history with the Company. As of December 31, 2023, 37% of the Company’s accounts receivable were due from one customer with an established credit history with the Company. The Company sells products to a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenue. During the three months ended June 30, 2024, the Company earned a total net revenue before excise taxes of $19,941 from two major customers, together accounting for 52% of the Company’s total net revenues before excise taxes. During the three months ended June 30, 2023, the Company earned a total net revenue before excise taxes of $16,839 from three major customers, together accounting for 67% of the Company’s total net revenues before excise taxes. During the six months ended June 30, 2024, the Company earned a total net revenue before excise taxes of $45,482 from three customers, together accounting for 62% of the Company’s total net revenues before excise taxes. During the six months ended June 30, 2023, the Company earned a total net revenue before excise taxes of $34,732 from three major customers, together accounting for 67% of the Company’s total net revenue before excise taxes. (g) New accounting pronouncements not yet adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information on the CODM and disclosures for entities with a single reportable segment. Additionally, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and we expect to adopt ASU 2023-07 retrospectively. The Company does not expect the adoption of ASU 2023-07 to have a material impact on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 enhances the existing income tax disclosures to provide additional information to better assess how an entity’s operations, related tax risks and tax planning, and operational opportunities affect its tax rate and prospects for future cash flows. ASU 2023-09 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and we expect to adopt ASU 2023-09 prospectively. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its consolidated financial statements. (h) Adoption of new accounting pronouncements On January 1, 2024, the Company adopted ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. The adoption of ASU 2022-03 did not have a material impact on the Company’s condensed consolidated interim financial statements. With respect to the adoption of ASU 2022-03, see Note 4 “Investments” for discussion of the contractual restrictions related to the PharmaCann Option (as defined below).

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations In the second quarter of 2023, the Company exited its then-existing U.S. hemp-derived cannabinoid product operations. Accordingly, the net loss of the U.S. operations for the three and six months ended June 30, 2023 are reported separately as loss from discontinued operations on the condensed consolidated statements of net loss and comprehensive income (loss). There was no activity in discontinued operations for the three and six months ended June 30, 2024. The following table presents the major components comprising loss from discontinued operations in the condensed consolidated statements of operations for the three and six months ended June 30, 2023: Three months ended June 30, Six months ended June 30, 2023 Net revenue $ 380 $ 1,029 Cost of sales 848 2,044 Inventory write-down 839 839 Gross profit (1,307) (1,854) Operating expenses Sales and marketing 387 518 Research and development 18 20 General and administrative 213 736 Restructuring costs 534 534 Share-based compensation 5 21 Depreciation and amortization 5 13 Impairment loss on long-lived assets (i) 205 205 Total operating expenses 1,367 2,047 Interest income 3 8 Other, net (ii) (163) (163) Total other income (loss) (160) (155) Loss before income taxes (2,834) (4,056) Income tax expense (benefit) — — Net loss from discontinued operations $ (2,834) $ (4,056) (i) During the three and six months ended June 30, 2023, as a result of the exit of the U.S. operations, the Company recognized an impairment charge of $205 related to the right-of-use lease assets associated with the Company’s former U.S. manufacturing facility in Los Angeles, California. (ii) For the three and six months ended June 30, 2023, Other, net related to loss on disposal of assets that were part of the U.S. operations. The following tables present the Company’s discontinued operations revenue by major product category: Three months ended June 30, Six months ended June 30, 2023 Cannabis extracts 380 1,029 Net revenue $ 380 $ 1,029 The following tables summarize the Company’s discontinued operations restructuring activity for the three and six months ended June 30, 2023: Accrual as of April 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 Accrual as of January 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 The Company had no assets or liabilities presented in the condensed consolidated balance sheets related to its discontinued operations as of both June 30, 2024 and December 31, 2023. For the six months ended June 30, 2024, there were no purchases of property plant and equipment related to discontinued operations. For the six months ended June 30, 2023, purchases of property plant and equipment related to discontinued operations were $67.

Inventory, net

Inventory, net	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Inventory, net	Inventory, net Inventory, net is comprised of the following items: As of June 30, 2024 As of December 31, 2023 Raw materials $ 5,351 $ 4,795 Work-in-progress 9,116 10,593 Finished goods 14,367 14,819 Supplies and consumables 348 288 Total $ 29,182 $ 30,495

Investments

Investments	6 Months Ended
	Jun. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments (a) Equity method investments, net A reconciliation of the carrying amount of the investments in equity method investees, net is as follows: Ownership interest As of June 30, 2024 As of December 31, 2023 Cronos Growing Company Inc. (“Cronos GrowCo”) 50% $ 21,226 $ 19,488 $ 21,226 $ 19,488 The following is a summary of the Company’s share of net income (losses) from equity investments accounted for under the equity method of accounting: For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 Cronos GrowCo $ 917 $ 270 $ 2,365 $ (226) $ 917 $ 270 $ 2,365 $ (226) Beginning in the third quarter of 2024, the results of Cronos GrowCo will be consolidated into the results of the Company, and the Company’s investment in Cronos GrowCo will be reclassified as an intercompany transaction and eliminated upon consolidation. For more information, see Note 12 “ Subsequent Events. ” (b) Other investments Other investments consist of investments in common shares and options of two companies in the cannabis industry. PharmaCann Option On June 14, 2021, the Company purchased an option (the “PharmaCann Option”) to acquire 473,787 shares of Class A Common Stock of PharmaCann, Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. The PharmaCann Option is classified as an investment in an equity security without a readily determinable fair value. The Company measures the PharmaCann Option at cost less accumulated impairment charges, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. As of June 30, 2024 and December 31, 2023, based on updated information provided by PharmaCann in the second quarter, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 6.2% and 6.6%, respectively. The decrease in the Company’s ownership percentage since acquisition does not materially affect the Company’s rights under the PharmaCann Option. The PharmaCann Option is measured at fair value on a non-recurring basis and is a level 3 asset. See Note 10 “ Fair Value Measurements ” for more information on the fair value hierarchy. The PharmaCann Option is reported as Other investments on the consolidated balance sheet as of June 30, 2024 and December 31, 2023. During the first and second quarters of 2024, the Company identified adverse forecast changes in the financial performance of PharmaCann as indicators of impairment related to the PharmaCann Option and conducted analyses comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using the market approach. Under the market approach, the key assumptions are the selected multiples and the discount for lack of marketability. As a result of these analyses, the Company recorded non-cash impairment charges of $12,734 and $12,916 in the first and second quarters of 2024, respectively, as the difference between the carrying amount of the PharmaCann Option and its estimated fair value, in the condensed consolidated statements of net loss and comprehensive loss for the six months ended June 30, 2024. The Company may sell, transfer or dispose of the PharmaCann Option without PharmaCann’s prior written consent, subject to the following conditions: (i) any transferee of any part of the PharmaCann Option must comply with and commit to comply with all regulations issued by a governmental entity applicable to such transferee in all material respects; (ii) any transferee of any part of the PharmaCann Option must agree to be bound by the terms of the Option Purchase Agreement, dated as of June 14, 2021 (the “Option Purchase Agreement”), as a “Purchaser” thereunder; (iii) the Company may not split and/or transfer the PharmaCann Option, in the aggregate, to more than four persons (with certain exceptions); (iv) no transferee may be a Prohibited Assignee (as defined in the Option Purchase Agreement); and (v) subject to certain exceptions, in the event that the Company (or a Permitted Transferee of the whole PharmaCann Option) transfers less than all of the PharmaCann Option to any third party that is not a Permitted Transferee, certain governance and information rights terminate immediately, unless waived by the PharmaCann board of directors in its sole and absolute discretion. Additionally, in the event of an initial underwritten public offering of PharmaCann’s common stock pursuant to an effective registration statement, to the extent that holders of PharmaCann common stock are subject to any lock-up period imposed by the underwriter in connection therewith, the Company will, if applicable, execute a customary lock-up agreement on the same material terms and conditions as the other holders of common stock are subject to or as otherwise agreed between PharmaCann and the Company, subject to certain conditions with respect to the duration of the lock-up period. Vitura Health Limited (formerly known as Cronos Australia) The Company owns approximately 10% of the outstanding common shares of Vitura Health Limited (“Vitura”). The investment is considered an equity security with a readily determinable fair value. Changes in the fair value of the investment are recorded as gain (loss) on revaluation of financial instruments on the condensed consolidated statements of net loss and comprehensive loss. The following table summarizes the Company’s other investments activity: As of April 1, 2024 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2024 PharmaCann $ 12,916 $ — $ (12,916) $ — $ — Vitura 6,842 (3,755) — 81 3,168 $ 19,758 $ (3,755) $ (12,916) $ 81 $ 3,168 As of January 1, 2024 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2024 PharmaCann $ 25,650 $ — $ (25,650) $ — $ — Vitura 9,601 (6,097) — (336) 3,168 $ 35,251 $ (6,097) $ (25,650) $ (336) $ 3,168 As of April 1, 2023 Unrealized gain Impairment charges Foreign exchange effect As of June 30, 2023 PharmaCann $ 49,000 $ — $ — $ — $ 49,000 Vitura 13,833 5,194 — (102) 18,925 $ 62,833 $ 5,194 $ — $ (102) $ 67,925 As of January 1, 2023 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2023 PharmaCann $ 49,000 $ — $ — $ — $ 49,000 Vitura 21,993 (2,729) — (339) 18,925 $ 70,993 $ (2,729) $ — $ (339) $ 67,925

Loans Receivable, net

Loans Receivable, net	6 Months Ended
	Jun. 30, 2024
Receivables [Abstract]
Loans Receivable, net	Loans Receivable, net Loans receivable, net consists of the following: As of June 30, 2024 As of December 31, 2023 GrowCo Credit Facility $ 4,875 $ 5,034 Add: Current portion of accrued interest — 507 Total current portion of loans receivable, net 4,875 5,541 GrowCo Credit Facility 57,271 53,638 Mucci Promissory Note 13,929 13,379 Cannasoul Collaboration Loan 1,692 1,771 Add: Long-term portion of accrued interest 273 248 Total long-term portion of loans receivable, net 73,165 69,036 Total loans receivable, net $ 78,040 $ 74,577 Cronos GrowCo Credit Facility On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C$100,000 (the “GrowCo Credit Facility”). The GrowCo Credit Facility is secured by substantially all present and after-acquired personal and real property of Cronos GrowCo. In August 2021, the GrowCo Credit Facility was amended to increase the aggregate principal amount available to C$105,000. In June 2024, the GrowCo Credit Facility was amended to increase the aggregate principal amount available by C$70,000 by providing a second secured non-revolving credit facility (“Term Loan B”). The funds from Term Loan B will be used to expand Cronos GrowCo’s purpose-built cannabis facility and will mature 10 years after the commencement of sales from the expansion area, following which, principal will be repaid on a quarterly basis. Interest on Term Loan B is payable on a quarterly basis until maturity beginning after the first borrowing under Term Loan B. Prior to July 1, 2024, only C$12,000 of the C$70,000 increased principal availability could be drawn, which Cronos GrowCo drew in full on June 20, 2024. As of June 30, 2024 and December 31, 2023, Cronos GrowCo had drawn C$116,000 and C$104,000 ($84,833 and $78,532, respectively), respectively from the GrowCo Credit Facility. The interest rate on the outstanding borrowings is the Canadian Prime Rate plus 1.25%, with interest payments due quarterly. Principal payments of C$1,000 commenced in March 2022 and are currently C$1,667, due quarterly. For the three months ended June 30, 2024, Cronos GrowCo repaid C$1,667 ($1,216) in principal and C$1,920 ($1,401) in interest related to the GrowCo Credit Facility. For the six months ended June 30, 2024, Cronos GrowCo repaid C$3,333 ($2,447) in principal and C$3,862 ($2,835) in interest related to the GrowCo Credit Facility. As of June 30, 2024, Cronos GrowCo had repaid an aggregate C$14,833 ($10,848) and C$24,384 ($17,832) in principal and interest, respectively, under the terms of the GrowCo Credit Facility. Beginning in the third quarter of 2024, the results of Cronos GrowCo will be consolidated into the results of the Company, and the Cronos GrowCo Credit Facility will be reclassified as an intercompany transaction and eliminated upon consolidation. For more information, see Note 12 “ Subsequent Events. ” Mucci Promissory Note On June 28, 2019, the Company entered into a promissory note receivable agreement (the “Mucci Promissory Note”) for C$16,350 (approximately $11,957) with the Cronos GrowCo joint venture partner (“Mucci”). The Mucci Promissory Note is secured by a general security agreement covering all the assets of Mucci. On September 30, 2022, the Mucci Promissory Note was amended and restated to increase the interest rate from 3.95% to the Canadian Prime Rate plus 1.25%, change the interest payments from quarterly to annual, and defer Mucci’s initial cash interest payment from September 30, 2022 to July 1, 2023. On June 20, 2024, the Mucci Promissory Note was amended and restated. As a result, interest accrued on the Mucci Promissory Note between July 1, 2023 and July 1, 2024 was capitalized as part of the principal balance, which increased the loans receivable and decreased interest receivable by $974 on the condensed consolidated balance sheets as of June 30, 2024. As of July 1, 2024, interest is accrued and to be paid in cash beginning on July 1, 2025. Prior to July 1, 2022, interest accrued on the Mucci Promissory Note was capitalized as part of the principal balance. As of July 1, 2022, interest was accrued and to be paid in cash beginning on July 1, 2023. Prior to 2023, there were no repayments of principal or interest on the Mucci Promissory Note. For the three and six months ended June 30, 2023, Mucci made a payment of C$1,750 (approximately $1,322) under the Mucci Promissory Note, with C$1,187 ($897) related to accrued interest and C$563 ($425) related to outstanding principal. For the three and six months ended June 30, 2024, there were no repayments of principal or interest on the Mucci Promissory Note. Cannasoul Collaboration Loan As of both June 30, 2024 and December 31, 2023, Cannasoul Lab Services Ltd. has received ILS 8,297 (approximately $2,198 and $2,294, respectively), from the Cannasoul Collaboration Loan. Expected credit loss allowances on the Company’s long-term financial assets for the six months ended June 30, 2024 and 2023 were comprised of the following items: As of April 1, 2024 Increase (i) Foreign exchange effect As of June 30, 2024 GrowCo Credit Facility $ 10,740 $ 1,207 $ (109) $ 11,838 Mucci Promissory Note 89 1 — 90 Cannasoul Collaboration Loan 518 4 (16) 506 $ 11,347 $ 1,212 $ (125) $ 12,434 As of January 1, 2024 Increase (i) Foreign exchange effect As of June 30, 2024 GrowCo Credit Facility $ 11,176 $ 1,010 $ (348) $ 11,838 Mucci Promissory Note 89 3 (2) 90 Cannasoul Collaboration Loan 524 8 (26) 506 $ 11,789 $ 1,021 $ (376) $ 12,434 As of April 1, 2023 Increase (decrease) Foreign exchange effect As of June 30, 2023 GrowCo Credit Facility $ 11,719 $ (379) $ 239 $ 11,579 Mucci Promissory Note 91 (7) 2 86 Cannasoul Collaboration Loan 514 4 (15) 503 $ 12,324 $ (382) $ 226 $ 12,168 As of January 1, 2023 Increase (decrease) Foreign exchange effect As of June 30, 2023 GrowCo Credit Facility $ 12,455 $ (1,149) $ 273 $ 11,579 Mucci Promissory Note 89 (5) 2 86 Cannasoul Collaboration Loan 522 8 (27) 503 $ 13,066 $ (1,146) $ 248 $ 12,168 (i) During the three and six months ended June 30, 2024, $1,212 and $1,021, respectively, were recorded as increases to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive income (loss) primarily as a result of the increased loans under the GrowCo Credit Facility. During the three and six months ended June 30, 2023, $382 and $1,146, respectively, were recorded as decreases to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive income (loss) as a result of adjustments to our expected credit losses.

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the first quarter of 2022, the Company initiated a strategic plan to realign the business around its brands, centralize functions and evaluate the Company’s supply chain (the “Realignment”). As part of the Realignment, on February 28, 2022, the Board approved plans to leverage the Company’s strategic partnerships to improve supply chain efficiencies and reduce manufacturing overhead by exiting its production facility in Stayner, Ontario, Canada (the “Peace Naturals Campus”). On February 27, 2023, the Board approved revisions to the Realignment, which were expected to result in the Company maintaining select components of its operations at the Peace Naturals Campus, namely distribution warehousing, certain research and development activities and manufacturing of certain of the Company’s products, while seeking to sell and lease back all or some of the Peace Naturals Campus or to lease certain portions of the Peace Naturals Campus to third parties. In the third quarter of 2023, the Board approved revisions to the Realignment to wind-down operations at its Winnipeg, Manitoba facility (“Cronos Fermentation”), list the Cronos Fermentation facility for sale, and implement additional organization-wide cost reductions as the Company continues its Realignment initiatives. The Realignment initiatives were intended to position the Company to drive profitable and sustainable growth over time. On November 26, 2023, the Company entered into an agreement with Future Farmco Canada Inc. for the sale and leaseback of the Peace Naturals Campus. This agreement was subsequently terminated pursuant to its terms during the second quarter of 2024. The Company is continuing to evaluate its strategic options for the Peace Naturals Campus, which may include continuing and expanding operations at the facility. During the first quarter of 2024, the Company ceased operations at Cronos Fermentation and performed an assessment under ASC 360 of the recoverability of the carrying value of the Cronos Fermentation assets, and determined the carrying value of the assets was not fully recoverable. The fair value was estimated using a combination of the market and income approaches. As a result of this analysis, an impairment loss on long-lived assets of $1,631 was recorded to the condensed consolidated statements of net loss and comprehensive loss in the six months ended June 30, 2024. As of June 30, 2024, the assets of Cronos Fermentation met the held-for-sale criteria and were classified to assets held for sale on the condensed consolidated balance sheet and the assets are valued at their fair value less costs to sell. A $445 loss for estimated costs to sell was recorded in the six months ended June 30, 2024 as a result of the classification of the Cronos Fermentation assets as held for sale. During the three and six months ended June 30, 2024, the Company incurred $547 and $630 of restructuring costs in its continuing operations in connection with the Realignment. Charges related thereto include shutdown costs at the Cronos Fermentation facility, as well as employee-related costs such as severance and other termination benefits. During the three and six months ended June 30, 2023, the Company recognized no restructuring costs in continuing operations in connection with the Realignment. Restructuring costs incurred in the Company’s discontinued operations during the three and six months ended June 30, 2023 is presented in Note 2 “ Discontinued Operations .” The following table summarizes the Company’s restructuring activity for the three and six months ended June 30, 2024: Accrual as of April 1, 2024 Expenses Payments/Write-offs Accrual as of June 30, 2024 Employee Termination Benefits $ 38 $ — $ (14) $ 24 Other Restructuring Costs — 547 — 547 Total $ 38 $ 547 $ (14) $ 571 Accrual as of January 1, 2024 Expenses Payments/Write-offs Accrual as of June 30, 2024 Employee Termination Benefits $ 150 $ 62 $ (188) $ 24 Other Restructuring Costs — 568 (21) 547 Total $ 150 $ 630 $ (209) $ 571

Share-based Compensation

Share-based Compensation	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-based Compensation	Share-based Compensation (a) Share-based award plans The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan”), the Employment Inducement Award Plan #1 (the “Employment Inducement Award Plan”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU Plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the 2018 Stock Option Plan or the Employment Inducement Award Plan. The following table summarizes the total share-based compensation expense associated with the Company’s stock options and RSUs for the three and six months ended June 30, 2024 and 2023: For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 Stock options $ 33 $ 372 $ 67 $ 1,106 RSUs 2,203 1,959 4,184 3,760 Total share-based compensation $ 2,236 $ 2,331 $ 4,251 $ 4,866 (b) Stock options Vesting conditions for grants of options are determined by the Compensation Committee of the Company’s Board of Directors. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three three The following is a summary of the changes in stock options for the six months ended June 30, 2024 and 2023: Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2024 $ 14.50 2,103,201 1.84 Cancellation, forfeiture and expiry of options 19.05 (1,381,696) Balance as of June 30, 2024 $ 5.78 721,505 4.13 Exercisable as of June 30, 2024 $ 6.59 520,820 3.58 Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2023 $ 10.57 5,350,600 0.73 Issuance of options 2.96 188,317 Cancellation, forfeiture and expiry of options 7.75 (3,435,716) Balance as of June 30, 2023 $ 14.50 2,103,201 2.34 Exercisable as of June 30, 2023 $ 18.72 1,426,612 1.00 (i) The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. The following table summarizes stock options outstanding: As of June 30, 2024 As of December 31, 2023 2020 Omnibus Plan 702,264 702,264 2018 Stock Option Plan 19,241 1,400,937 Total stock options outstanding 721,505 2,103,201 Restricted share units The following is a summary of the changes in RSUs for the six months ended June 30, 2024 and 2023: Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2024 $ 3.77 7,381,541 Granted (i) 2.95 2,503,835 Vested and issued 3.53 (1,343,425) Cancellation and forfeitures 2.98 (91,726) Balance as of June 30, 2024 $ 3.57 8,450,225 Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2023 $ 4.63 5,725,470 Granted (i) 2.66 2,819,174 Vested and issued 5.04 (735,523) Cancellation and forfeitures 3.93 (254,382) Balance as of June 30, 2023 $ 3.87 7,554,739 (i) RSUs granted in the period vest annually in equal installments over a three-year period from either the grant date or after a three (ii) The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance. (d) Deferred share units The following is a summary of the changes in DSUs for the six months ended June 30, 2024 and 2023: Financial liability Number of DSUs Balance as of January 1, 2024 $ 1,092 521,679 DSU liabilities settled (359) (155,383) Loss on revaluation 122 — Balance as of June 30, 2024 $ 855 366,296 Financial liability Number of DSUs Balance as of January 1, 2023 $ 674 265,732 Gain on revaluation (150) — Balance as of June 30, 2023 $ 524 265,732

Loss per Share

Loss per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Loss per Share	Loss per Share Basic and diluted loss per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts): Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Basic loss per share computation Net loss from continuing operations attributable to the shareholders of Cronos Group $ (8,757) $ (5,526) $ (10,998) $ (23,473) Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share (i) 382,157,555 380,961,682 381,800,078 380,792,802 Basic loss from continuing operations per share $ (0.02) $ (0.01) $ (0.03) $ (0.06) Diluted loss per share from continuing operations $ (0.02) $ (0.01) $ (0.03) $ (0.06) Loss from discontinued operations attributable to the shareholders of Cronos Group $ — $ (2,834) $ — $ (4,056) Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share (i) 382,157,555 380,961,682 381,800,078 380,792,802 Basic loss from discontinued operations per share $ — $ (0.01) $ — $ (0.01) Diluted loss from discontinued operations per share $ — $ (0.01) $ — $ (0.01) (i) In computing diluted loss per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive. For the three months ended June 30, 2024 and 2023, total securities of 19,434,059 and 28,769,758, respectively, were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive. For the six months ended June 30, 2024 and 2023, total securities of 22,007,363 and 29,428,093, respectively, were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Loss Contingency [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a) Commitments There have been no material changes in the information regarding commitments as disclosed in the Company’s Annual Report. (b) Contingencies The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its financial condition but could be material to its results of operations for a quarterly period depending, in part, on its results for that quarter. (i) Class action complaints relating to restatement of 2019 interim financial statements On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its Chief Executive Officer and former Chief Financial Officer. The court consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5, promulgated thereunder, against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenues and internal controls were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board of Directors’ review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. The defendants moved to dismiss on February 8, 2021. On November 17, 2023, the court entered an order granting the motion and dismissed the case with prejudice. On December 1, 2023, the shareholder plaintiffs sought reconsideration of the dismissal, requesting that the court instead dismiss the action without prejudice and permit the plaintiffs to seek leave to further amend the complaint. The reconsideration motion is pending. On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim named (i) the Company, (ii) its Chief Executive Officer, (iii) former Chief Financial Officer, (iv) former Chief Financial Officer and Chief Commercial Officer, and (v) current and former members of the Board as defendants and alleged breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleged that certain of the Company’s prior public statements about revenues and internal controls were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board of Directors was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim did not quantify a damage request. On June 28, 2021, the Court dismissed motions brought by the plaintiff for leave to commence a claim for misrepresentation under the Ontario Securities Act and for certification of the action as a class action. The plaintiff appealed the Court’s dismissal of the motions only with respect to the Company, the Chief Executive Officer, and the now former Chief Financial Officer; the remaining defendants were dismissed from the matter with prejudice and the Company and all individual defendants agreed not to seek costs from plaintiff in connection with the dismissal of the motions. On September 26, 2022, the Court of Appeal for Ontario reversed the Superior Court’s dismissal of the leave and certification motions, granted the plaintiff leave to proceed to bring a claim for misrepresentation under the Ontario Securities Act, and remitted the certification motion back to the Superior Court. On April 11, 2023, the plaintiff filed a Fresh as Amended Statement of Claim, which reflected the dismissal of the defendants for which an appeal was not sought, the removal of the claims for oppression under the Ontario Business Corporations Act and common law misrepresentation, as well as shortening the proposed class period. On October 10, 2023, the Superior Court certified the action on behalf of a class of persons or entities who acquired shares in the secondary market, including on the TSX and Nasdaq, during the period from May 9, 2019 to March 30, 2020, other than certain excluded persons. (ii) Regulatory reviews relating to restatements On October 24, 2022, the Company announced regulatory settlements as follows: SEC Settlement On October 24, 2022, the SEC issued an Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8(a) of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21(c) of the Exchange Act, Making Findings, and Imposing a Cease-and-Desist Order (the “Settlement Order”) resolving the Restatements. The Company agreed to settle with the SEC, without admitting or denying the allegations described in the Settlement Order. The Settlement Order fully and finally disposed of the investigation of the Company by the SEC into the Restatements without the payment of any civil penalty or other amount. The Settlement Order required the Company to cease and desist from committing or causing any violations and any future violations of Section 17(a) of the Securities Act, Sections 10(b), 13(a), 13(b)(2)(B) of the Exchange Act and Rules 10b-5, 13a-13, 13a-15(a), 13a-16 and 12b-20 thereunder. As a result of the Settlement Order, the Company (i) lost its status as a well-known seasoned issuer for a period of three years, (ii) is unable to rely on the private offering exemptions provided by Regulations A and D under the Securities Act for a period of five years and (iii) is unable to rely on the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 for a period of three years. OSC Settlement On October 24, 2022, the Ontario Capital Markets Tribunal approved a settlement agreement (the “Settlement Agreement”) between the Company and the staff of the Ontario Securities Commission (the “OSC”), resolving the Restatements. Pursuant to the terms of the Settlement Agreement, which fully and finally disposed the investigation of the Company by the OSC, Cronos agreed to pay a total of C$1.34 million to fully settle the matter, and acknowledged that it had failed to comply with the requirement under Section 77 of the Ontario Securities Act to file interim financial reports in the manner set out therein and had acted in a manner contrary to the public interest. (iii) Litigation and regulatory inquiries relating to marketing, distribution, import and sale of products On April 17, 2023, a group of plaintiffs led by the Green Leaf (Ale Yarok) political party filed a Statement of Claim and Request for Approval of a Class Action on behalf of a purported class of Israeli cannabis consumers in the District Court of Tel Aviv, Israel, against 26 cannabis-related parties, including three Cronos Israel entities. The Statement of Claim alleges that the defendants violated certain laws relating to the marketing of medical cannabis products, including marketing to unlicensed cannabis consumers. The lawsuit seeks a total of ILS 420 million. The Cronos Israel defendants moved to dismiss the action on August 13, 2023. The court granted the motion (and similar motions filed by other defendants) on May 16, 2024, dismissing the plaintiffs’ petition for class certification without prejudice and their individual claims with prejudice, and ordering the plaintiffs to pay ILS 10 thousand to each of the defendants for costs. On July 14, 2024, the plaintiffs appealed to the Supreme Court of Israel seeking to overturn both the dismissal of plaintiffs’ individual claims and the award of costs. The appeal is pending. On January 18, 2024, the Company was notified that the Trade Levies Commissioner of the Israel Ministry of Economy and Industry initiated a public investigation of alleged dumping of medical cannabis imports from Canada into Israel. On July 9, 2024, the Commissioner announced a preliminary determination proposing to impose an anti-dumping duty on Canadian licensed producers. The Company would be subject to a proposed duty of 369%. The Commissioner determined not to impose a provisional duty at this time pending the conclusion of the Ministry’s investigation. The Company previously responded to requests for information from the Ministry and is providing additional information. The Company cannot predict the outcome of the investigation. We expect litigation and regulatory proceedings relating to the marketing, distribution, import and sale of our products to increase.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Risks and Uncertainties [Abstract]
Fair Value Measurements	Fair Value Measurements The Company complies with ASC 820 Fair Value Measurements for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by: • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. • Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: June 30, 2024 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 848,189 $ — $ — $ 848,189 Other investments (i) 3,168 — — 3,168 Derivative liabilities — — 21 21 December 31, 2023 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 669,291 $ — $ — $ 669,291 Short-term investments 192,237 — — 192,237 Other investments (i) 9,601 — — 9,601 Derivative liabilities — — 102 102 (i) As of June 30, 2024 and December 31, 2023, the Company’s influence on Vitura is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 4 “ Investments ” for additional information. There were no transfers between fair value categories during the periods presented. The following tables present information about the Company’s assets that are measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: As of June 30, 2024 Level 1 Level 2 Level 3 Total Other investments (i) $ — $ — $ — $ — As of December 31, 2023 Level 1 Level 2 Level 3 Total Other investments (i) $ — $ — $ 25,650 $ 25,650 (i) On June 14, 2021, the Company purchased an option to acquire 473,787 shares of Class A Common Stock of PharmaCann, a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. As of June 30, 2024 and December 31, 2023, based on updated information provided by PharmaCann in the first quarter, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 6.2% and 6.6%. In the three and six months ended June 30, 2024, the PharmaCann Option was impaired to zero. See Note 4 “ Investments .” There were no transfers between fair value categories during the periods presented.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions (a) Cronos GrowCo The Company holds a variable interest in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt in Cronos GrowCo. See Note 4 “ Investments ” for additional information. The Company made the following purchases of cannabis products from Cronos GrowCo: Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Cronos GrowCo – purchases $ 9,942 $ 6,549 $ 16,952 $ 14,015 As of June 30, 2024, and December 31, 2023, the Company had payables outstanding to Cronos GrowCo of $1,640 and $2,267, respectively. During the third quarter of 2023, the Company, as supplier, entered into a cannabis germplasm supply agreement with Cronos GrowCo as buyer. During the three and six months ended June 30, 2024, the Company received $266 and $627, respectively, in relation to this agreement. Additionally, on August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into the GrowCo Credit Facility. In August 2021, the GrowCo Credit Facility was amended to increase the aggregate principal amount available. In June 2024, the GrowCo Credit Facility was further amended to increase the aggregate principal amount available by providing a second secured non-revolving credit facility. See Note 5 “ Loans Receivable, net ” for additional information. On June 20, 2024, the Company entered into an amended and restated supply agreement with Cronos GrowCo (the “Supply Agreement”). Pursuant to the terms of the Supply Agreement, prior to the commencement of sales from Cronos GrowCo’s Phase 2 expansion area, the Company and its affiliates have the right, but not the obligation, to purchase an aggregate total quantity of 80% of what is produced by Cronos GrowCo. Thereafter, the Company and its affiliates will have the right, but not the obligation, to purchase 70% of Cronos GrowCo’s forecasted production capacity over a given period and 70% of Cronos GrowCo’s actual production in a given month. All prices for products purchased pursuant to the Supply Agreement are fixed throughout the four year term of the Supply Agreement. Beginning in the third quarter of 2024, the results of Cronos GrowCo will be consolidated into the results of the Company, and all transactions with Cronos GrowCo will be treated as intercompany transactions and eliminated upon consolidation. For more information, see Note 12 “ Subsequent Events. ” (b) Vendor Agreement In November 2022, the Company entered into an agreement with an external vendor whereby the vendor would provide certain manufacturing services to the Company. The vendor then subcontracted out a portion of those services to another company whose chief executive officer is an immediate family member of an executive of the Company. The Company purchased $603 and $1,436 of products and services under this subcontracted agreement for the three and six months ended June 30, 2023. The Company had $0 and $28 in outstanding payables related to the subcontracted agreement as of June 30, 2024 and December 31, 2023, respectively. In November 2023, the Company negotiated a direct contract with the related-party vendor. During the three and six months ended June 30, 2024, the Company purchased $260 and $936 of products and services under this agreement and had outstanding accounts payable related to the agreement of $7 and $11 as of June 30, 2024 and December 31, 2023, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events (a) Cronos GrowCo Amended Shareholders’ Agreement On July 1, 2024, the Company attained majority control of the board of directors of Cronos GrowCo. As a result, the Company will consolidate the results of operations of Cronos GrowCo in its condensed consolidated financial statements beginning in the third quarter of 2024. The consolidation of Cronos GrowCo results in a business combination under ASC 805. Acquisition costs of $196 were recorded to general and administrative expense on the condensed consolidated statements of loss and comprehensive income (loss) in the three and six months ended June 30, 2024. The initial accounting for the GrowCo business combination is incomplete as of the issuance of these financial statements. In addition, we have not yet completed our valuations of certain assets, including inventory, fixed assets and intangible assets. As such, it is impracticable to provide certain pro-forma financial information, information on the acquisition-date fair value of our equity interest in GrowCo or the allocation of fair value to the acquired GrowCo assets and liabilities.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ (8,757)	$ (8,360)	$ (10,998)	$ (27,529)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Background, Basis of Presenta_2

Background, Basis of Presentation, and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation These condensed consolidated interim financial statements of Cronos are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”). Certain prior period amounts have been reclassified to conform to the current year presentation of our condensed consolidated interim financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity.
Discontinued Operations	Discontinued Operations In the second quarter of 2023, the Company exited its U.S. hemp-derived cannabinoid product operations. The exit of the U.S. operations represented a strategic shift that had a major effect on the Company’s operations and financial results, and as such, qualifies for reporting as discontinued operations in our condensed consolidated statements of net loss and comprehensive income (loss). Prior period amounts have been reclassified to reflect the discontinued operations classification of the U.S. operations. For more information, see Note 2 “ Discontinued Operations. ”
Segment information	Segment information Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. Prior to the second quarter of 2023, the Company reported results for two reportable segments, the U.S. and Rest of World. In the second quarter of 2023, as a result of the Company’s exit of its then-existing U.S. operations, the Company determined that it has one operating segment and therefore one reportable segment, which is comprised of operations in Canada and Israel and is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets . All prior period segment disclosure information has been reclassified to conform to the current reporting structure in this Form 10-Q. These reclassifications had no effect on our consolidated financial statements in any period presented.
Concentration of risk	Concentration of risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments and loans receivable. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $954,818 and $966,442 as of June 30, 2024 and December 31, 2023, respectively.
New accounting pronouncement not yet adopted and Adoption of new accounting pronouncements	New accounting pronouncements not yet adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses, information on the CODM and disclosures for entities with a single reportable segment. Additionally, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and we expect to adopt ASU 2023-07 retrospectively. The Company does not expect the adoption of ASU 2023-07 to have a material impact on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 enhances the existing income tax disclosures to provide additional information to better assess how an entity’s operations, related tax risks and tax planning, and operational opportunities affect its tax rate and prospects for future cash flows. ASU 2023-09 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and we expect to adopt ASU 2023-09 prospectively. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its consolidated financial statements. (h) Adoption of new accounting pronouncements On January 1, 2024, the Company adopted ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. The adoption of ASU 2022-03 did not have a material impact on the Company’s condensed consolidated interim financial statements. With respect to the adoption of ASU 2022-03, see Note 4 “Investments” for discussion of the contractual restrictions related to the PharmaCann Option (as defined below).

Background, Basis of Presenta_3

Background, Basis of Presentation, and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Revenue by Major Product Category	The following tables present the Company’s revenue by major product category for continuing operations: Three months ended June 30, 2024 2023 Cannabis flower $ 20,661 $ 14,014 Cannabis extracts 7,064 4,926 Other 37 81 Net revenue $ 27,762 $ 19,021 Six months ended June 30, 2024 2023 Cannabis flower $ 38,186 $ 27,142 Cannabis extracts 14,791 11,227 Other 73 147 Net revenue $ 53,050 $ 38,516
Schedule of Revenue from External Customers by Geographic Areas	Net revenue attributed to a geographic region based on the location of the customer were as follows for continuing operations: Three months ended June 30, 2024 2023 Canada $ 19,844 $ 13,595 Israel 6,889 5,426 Other countries 1,029 — Net revenue $ 27,762 $ 19,021 Six months ended June 30, 2024 2023 Canada $ 38,715 $ 28,029 Israel 13,306 10,487 Other countries 1,029 — Net revenue $ 53,050 $ 38,516

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Summary of Financial Information for Discontinued Operations	The following table presents the major components comprising loss from discontinued operations in the condensed consolidated statements of operations for the three and six months ended June 30, 2023: Three months ended June 30, Six months ended June 30, 2023 Net revenue $ 380 $ 1,029 Cost of sales 848 2,044 Inventory write-down 839 839 Gross profit (1,307) (1,854) Operating expenses Sales and marketing 387 518 Research and development 18 20 General and administrative 213 736 Restructuring costs 534 534 Share-based compensation 5 21 Depreciation and amortization 5 13 Impairment loss on long-lived assets (i) 205 205 Total operating expenses 1,367 2,047 Interest income 3 8 Other, net (ii) (163) (163) Total other income (loss) (160) (155) Loss before income taxes (2,834) (4,056) Income tax expense (benefit) — — Net loss from discontinued operations $ (2,834) $ (4,056) (i) During the three and six months ended June 30, 2023, as a result of the exit of the U.S. operations, the Company recognized an impairment charge of $205 related to the right-of-use lease assets associated with the Company’s former U.S. manufacturing facility in Los Angeles, California. (ii) For the three and six months ended June 30, 2023, Other, net related to loss on disposal of assets that were part of the U.S. operations. The following tables present the Company’s discontinued operations revenue by major product category: Three months ended June 30, Six months ended June 30, 2023 Cannabis extracts 380 1,029 Net revenue $ 380 $ 1,029
Schedule of Discontinued Operations Restructuring Activity	The following tables summarize the Company’s discontinued operations restructuring activity for the three and six months ended June 30, 2023: Accrual as of April 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 Accrual as of January 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 The following table summarizes the Company’s restructuring activity for the three and six months ended June 30, 2024: Accrual as of April 1, 2024 Expenses Payments/Write-offs Accrual as of June 30, 2024 Employee Termination Benefits $ 38 $ — $ (14) $ 24 Other Restructuring Costs — 547 — 547 Total $ 38 $ 547 $ (14) $ 571 Accrual as of January 1, 2024 Expenses Payments/Write-offs Accrual as of June 30, 2024 Employee Termination Benefits $ 150 $ 62 $ (188) $ 24 Other Restructuring Costs — 568 (21) 547 Total $ 150 $ 630 $ (209) $ 571

Inventory, net (Tables)

Inventory, net (Tables)	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory, net	Inventory, net is comprised of the following items: As of June 30, 2024 As of December 31, 2023 Raw materials $ 5,351 $ 4,795 Work-in-progress 9,116 10,593 Finished goods 14,367 14,819 Supplies and consumables 348 288 Total $ 29,182 $ 30,495

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Investments in Associates and Joint Ventures	A reconciliation of the carrying amount of the investments in equity method investees, net is as follows: Ownership interest As of June 30, 2024 As of December 31, 2023 Cronos Growing Company Inc. (“Cronos GrowCo”) 50% $ 21,226 $ 19,488 $ 21,226 $ 19,488 The following is a summary of the Company’s share of net income (losses) from equity investments accounted for under the equity method of accounting: For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 Cronos GrowCo $ 917 $ 270 $ 2,365 $ (226) $ 917 $ 270 $ 2,365 $ (226)
Summary of Gain on Revaluation of Other Investments	The following table summarizes the Company’s other investments activity: As of April 1, 2024 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2024 PharmaCann $ 12,916 $ — $ (12,916) $ — $ — Vitura 6,842 (3,755) — 81 3,168 $ 19,758 $ (3,755) $ (12,916) $ 81 $ 3,168 As of January 1, 2024 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2024 PharmaCann $ 25,650 $ — $ (25,650) $ — $ — Vitura 9,601 (6,097) — (336) 3,168 $ 35,251 $ (6,097) $ (25,650) $ (336) $ 3,168 As of April 1, 2023 Unrealized gain Impairment charges Foreign exchange effect As of June 30, 2023 PharmaCann $ 49,000 $ — $ — $ — $ 49,000 Vitura 13,833 5,194 — (102) 18,925 $ 62,833 $ 5,194 $ — $ (102) $ 67,925 As of January 1, 2023 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2023 PharmaCann $ 49,000 $ — $ — $ — $ 49,000 Vitura 21,993 (2,729) — (339) 18,925 $ 70,993 $ (2,729) $ — $ (339) $ 67,925

Loans Receivable, net (Tables)

Loans Receivable, net (Tables)	6 Months Ended
	Jun. 30, 2024
Receivables [Abstract]
Schedule of Loans Receivable	Loans receivable, net consists of the following: As of June 30, 2024 As of December 31, 2023 GrowCo Credit Facility $ 4,875 $ 5,034 Add: Current portion of accrued interest — 507 Total current portion of loans receivable, net 4,875 5,541 GrowCo Credit Facility 57,271 53,638 Mucci Promissory Note 13,929 13,379 Cannasoul Collaboration Loan 1,692 1,771 Add: Long-term portion of accrued interest 273 248 Total long-term portion of loans receivable, net 73,165 69,036 Total loans receivable, net $ 78,040 $ 74,577
Schedule of Expected Credit Loss Allowances	Expected credit loss allowances on the Company’s long-term financial assets for the six months ended June 30, 2024 and 2023 were comprised of the following items: As of April 1, 2024 Increase (i) Foreign exchange effect As of June 30, 2024 GrowCo Credit Facility $ 10,740 $ 1,207 $ (109) $ 11,838 Mucci Promissory Note 89 1 — 90 Cannasoul Collaboration Loan 518 4 (16) 506 $ 11,347 $ 1,212 $ (125) $ 12,434 As of January 1, 2024 Increase (i) Foreign exchange effect As of June 30, 2024 GrowCo Credit Facility $ 11,176 $ 1,010 $ (348) $ 11,838 Mucci Promissory Note 89 3 (2) 90 Cannasoul Collaboration Loan 524 8 (26) 506 $ 11,789 $ 1,021 $ (376) $ 12,434 As of April 1, 2023 Increase (decrease) Foreign exchange effect As of June 30, 2023 GrowCo Credit Facility $ 11,719 $ (379) $ 239 $ 11,579 Mucci Promissory Note 91 (7) 2 86 Cannasoul Collaboration Loan 514 4 (15) 503 $ 12,324 $ (382) $ 226 $ 12,168 As of January 1, 2023 Increase (decrease) Foreign exchange effect As of June 30, 2023 GrowCo Credit Facility $ 12,455 $ (1,149) $ 273 $ 11,579 Mucci Promissory Note 89 (5) 2 86 Cannasoul Collaboration Loan 522 8 (27) 503 $ 13,066 $ (1,146) $ 248 $ 12,168 (i) During the three and six months ended June 30, 2024, $1,212 and $1,021, respectively, were recorded as increases to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive income (loss) primarily as a result of the increased loans under the GrowCo Credit Facility. During the three and six months ended June 30, 2023, $382 and $1,146, respectively, were recorded as decreases to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive income (loss) as a result of adjustments to our expected credit losses.

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of Plan Information and Restructuring-Related Costs	The following tables summarize the Company’s discontinued operations restructuring activity for the three and six months ended June 30, 2023: Accrual as of April 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 Accrual as of January 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 The following table summarizes the Company’s restructuring activity for the three and six months ended June 30, 2024: Accrual as of April 1, 2024 Expenses Payments/Write-offs Accrual as of June 30, 2024 Employee Termination Benefits $ 38 $ — $ (14) $ 24 Other Restructuring Costs — 547 — 547 Total $ 38 $ 547 $ (14) $ 571 Accrual as of January 1, 2024 Expenses Payments/Write-offs Accrual as of June 30, 2024 Employee Termination Benefits $ 150 $ 62 $ (188) $ 24 Other Restructuring Costs — 568 (21) 547 Total $ 150 $ 630 $ (209) $ 571

Share-based Compensation (Table

Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Stock-based Compensation Expense	The following table summarizes the total share-based compensation expense associated with the Company’s stock options and RSUs for the three and six months ended June 30, 2024 and 2023: For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 Stock options $ 33 $ 372 $ 67 $ 1,106 RSUs 2,203 1,959 4,184 3,760 Total share-based compensation $ 2,236 $ 2,331 $ 4,251 $ 4,866
Summary of the Changes in Options and Options Outstanding	The following is a summary of the changes in stock options for the six months ended June 30, 2024 and 2023: Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2024 $ 14.50 2,103,201 1.84 Cancellation, forfeiture and expiry of options 19.05 (1,381,696) Balance as of June 30, 2024 $ 5.78 721,505 4.13 Exercisable as of June 30, 2024 $ 6.59 520,820 3.58 Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2023 $ 10.57 5,350,600 0.73 Issuance of options 2.96 188,317 Cancellation, forfeiture and expiry of options 7.75 (3,435,716) Balance as of June 30, 2023 $ 14.50 2,103,201 2.34 Exercisable as of June 30, 2023 $ 18.72 1,426,612 1.00 (i) The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. The following table summarizes stock options outstanding: As of June 30, 2024 As of December 31, 2023 2020 Omnibus Plan 702,264 702,264 2018 Stock Option Plan 19,241 1,400,937 Total stock options outstanding 721,505 2,103,201
Summary of Changes in RSUs	The following is a summary of the changes in RSUs for the six months ended June 30, 2024 and 2023: Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2024 $ 3.77 7,381,541 Granted (i) 2.95 2,503,835 Vested and issued 3.53 (1,343,425) Cancellation and forfeitures 2.98 (91,726) Balance as of June 30, 2024 $ 3.57 8,450,225 Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2023 $ 4.63 5,725,470 Granted (i) 2.66 2,819,174 Vested and issued 5.04 (735,523) Cancellation and forfeitures 3.93 (254,382) Balance as of June 30, 2023 $ 3.87 7,554,739 (i) RSUs granted in the period vest annually in equal installments over a three-year period from either the grant date or after a three (ii)
Summary of Changes in DSUs and Warrants	The following is a summary of the changes in DSUs for the six months ended June 30, 2024 and 2023: Financial liability Number of DSUs Balance as of January 1, 2024 $ 1,092 521,679 DSU liabilities settled (359) (155,383) Loss on revaluation 122 — Balance as of June 30, 2024 $ 855 366,296 Financial liability Number of DSUs Balance as of January 1, 2023 $ 674 265,732 Gain on revaluation (150) — Balance as of June 30, 2023 $ 524 265,732

Loss per Share (Tables)

Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share	Basic and diluted loss per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts): Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Basic loss per share computation Net loss from continuing operations attributable to the shareholders of Cronos Group $ (8,757) $ (5,526) $ (10,998) $ (23,473) Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share (i) 382,157,555 380,961,682 381,800,078 380,792,802 Basic loss from continuing operations per share $ (0.02) $ (0.01) $ (0.03) $ (0.06) Diluted loss per share from continuing operations $ (0.02) $ (0.01) $ (0.03) $ (0.06) Loss from discontinued operations attributable to the shareholders of Cronos Group $ — $ (2,834) $ — $ (4,056) Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share (i) 382,157,555 380,961,682 381,800,078 380,792,802 Basic loss from discontinued operations per share $ — $ (0.01) $ — $ (0.01) Diluted loss from discontinued operations per share $ — $ (0.01) $ — $ (0.01) (i) In computing diluted loss per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Risks and Uncertainties [Abstract]
Schedule of Fair Value of Assets Measured on Recurring Basis	The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: June 30, 2024 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 848,189 $ — $ — $ 848,189 Other investments (i) 3,168 — — 3,168 Derivative liabilities — — 21 21 December 31, 2023 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 669,291 $ — $ — $ 669,291 Short-term investments 192,237 — — 192,237 Other investments (i) 9,601 — — 9,601 Derivative liabilities — — 102 102 (i) As of June 30, 2024 and December 31, 2023, the Company’s influence on Vitura is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 4 “ Investments ” for additional information.
Schedule of Fair Value of Assets Measured on Nonrecurring Basis	The following tables present information about the Company’s assets that are measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: As of June 30, 2024 Level 1 Level 2 Level 3 Total Other investments (i) $ — $ — $ — $ — As of December 31, 2023 Level 1 Level 2 Level 3 Total Other investments (i) $ — $ — $ 25,650 $ 25,650 (i) On June 14, 2021, the Company purchased an option to acquire 473,787 shares of Class A Common Stock of PharmaCann, a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. As of June 30, 2024 and December 31, 2023, based on updated information provided by PharmaCann in the first quarter, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 6.2% and 6.6%. In the three and six months ended June 30, 2024, the PharmaCann Option was impaired to zero. See Note 4 “ Investments .”

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The Company made the following purchases of cannabis products from Cronos GrowCo: Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Cronos GrowCo – purchases $ 9,942 $ 6,549 $ 16,952 $ 14,015

Background, Basis of Presenta_4

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($) segment	Mar. 31, 2023 segment	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Concentration Risk [Line Items]
Number of reportable segments | segment		1	2
Number of operating segments | segment		1
Maximum exposure to credit risk				$ 954,818		$ 966,442
Current expected credit loss allowance on accounts receivable	$ 20			20		$ 3
Net revenue, before excise taxes	38,678	$ 25,798		74,045	$ 52,352
Two Major Customers
Concentration Risk [Line Items]
Net revenue, before excise taxes	$ 19,941
Three Major Customers
Concentration Risk [Line Items]
Net revenue, before excise taxes				$ 45,482
Accounts Receivable | One Customer | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage				30%		37%
Revenue Benchmark | Two Major Customers | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	52%
Revenue Benchmark | Three Major Customers | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage		67%		62%	67%
Net revenue, before excise taxes		$ 16,839			$ 34,732

Background, Basis of Presenta_5

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Segment Reporting Information [Line Items]
Net revenue	$ 27,762	$ 19,021	$ 53,050	$ 38,516
Canada
Segment Reporting Information [Line Items]
Net revenue	19,844	13,595	38,715	28,029
Israel
Segment Reporting Information [Line Items]
Net revenue	6,889	5,426	13,306	10,487
Other countries
Segment Reporting Information [Line Items]
Net revenue	1,029	0	1,029	0
Cannabis flower
Segment Reporting Information [Line Items]
Net revenue	20,661	14,014	38,186	27,142
Cannabis extracts
Segment Reporting Information [Line Items]
Net revenue	7,064	4,926	14,791	11,227
Other
Segment Reporting Information [Line Items]
Net revenue	$ 37	$ 81	$ 73	$ 147

Discontinued Operations - Major

Discontinued Operations - Major Components Comprising Loss from Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expenses
Net loss from discontinued operations	$ 0	$ (2,834)	$ 0	$ (4,056)
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue		380		1,029
Cost of sales		848		2,044
Inventory write-down		839		839
Gross profit		(1,307)		(1,854)
Operating expenses
Sales and marketing		387		518
Research and development		18		20
General and administrative		213		736
Restructuring costs		534		534
Share-based compensation		5		21
Depreciation and amortization		5		13
Impairment loss on long-lived assets		205		205
Total operating expenses		1,367		2,047
Interest income		3		8
Other, net		(163)		(163)
Total other income (loss)		(160)		(155)
Loss before income taxes		(2,834)		(4,056)
Income tax expense (benefit)		0		0
Net loss from discontinued operations		(2,834)		(4,056)
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment | Facility in Los Angeles, California
Operating expenses
Impairment loss on long-lived assets		$ 205		$ 205

Discontinued Operations - Reven

Discontinued Operations - Revenue by Major Product Category (Details) - Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 380	$ 1,029
Cannabis extracts
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 380	$ 1,029

Discontinued Operations - Restr

Discontinued Operations - Restructuring Activity (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Restructuring Reserve [Roll Forward]
Expenses	$ 547	$ 0	$ 630	$ 0
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance		0		0
Expenses		534		534
Payments/Write-offs		(223)		(223)
Accrual, Ending Balance		311		311
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment | Employee termination benefits
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance		0		0
Expenses		442		442
Payments/Write-offs		(223)		(223)
Accrual, Ending Balance		219		219
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment | Other restructuring costs
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance		0		0
Expenses		92		92
Payments/Write-offs		0		0
Accrual, Ending Balance		$ 92		$ 92

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase of property, plant and equipment	$ 2,453	$ 1,298
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase of property, plant and equipment	$ 0	$ 67

Inventory, net (Details)

Inventory, net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 5,351	$ 4,795
Work-in-progress	9,116	10,593
Finished goods	14,367	14,819
Supplies and consumables	348	288
Inventory, net	$ 29,182	$ 30,495

Investments - Schedule of Inves

Investments - Schedule of Investments in Associates and Joint Ventures (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]
Equity method investments, net	$ 21,226		$ 21,226		$ 19,488
Share of income (loss) from equity method investments	$ 917	$ 270	$ 2,365	$ (226)
Cronos GrowCo
Schedule of Equity Method Investments [Line Items]
Ownership interest	50%		50%
Equity method investments, net	$ 21,226		$ 21,226		$ 19,488
Share of income (loss) from equity method investments	$ 917	$ 270	$ 2,365	$ (226)

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended			6 Months Ended
	Jun. 14, 2021	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Variable Interest Entity [Line Items]
Sale of stock, price per share (in dollars per share)	$ 0.0001
Sale of stock, percentage of ownership after transaction	10.50%
Purchase of other investments	$ 110,392
Impairment loss on other investments		$ 12,916		$ 0	$ 25,650	$ 0
Vitura
Variable Interest Entity [Line Items]
Impairment loss on other investments		0		0	0	0
PharmaCann
Variable Interest Entity [Line Items]
Impairment loss on other investments		$ 12,916	$ 12,734	$ 0	$ 25,650	$ 0
PharmaCann
Variable Interest Entity [Line Items]
Ownership interest		6.20%			6.20%		6.60%
Vitura
Variable Interest Entity [Line Items]
Ownership interest		10%			10%
PharmaCann
Variable Interest Entity [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	473,787

Investments - Revaluation of Ot

Investments - Revaluation of Other Investments (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Other Investments [Roll Forward]
Other investments, beginning balance	$ 19,758	$ 35,251	$ 62,833	$ 35,251	$ 70,993
Unrealized gain (loss)	(3,755)		5,194	(6,097)	(2,729)
Impairment charges	(12,916)		0	(25,650)	0
Foreign exchange effect	81		(102)	(336)	(339)
Other investments, ending balance	3,168	19,758	67,925	3,168	67,925
PharmaCann
Other Investments [Roll Forward]
Other investments, beginning balance	12,916	25,650	49,000	25,650	49,000
Unrealized gain (loss)	0		0	0	0
Impairment charges	(12,916)	(12,734)	0	(25,650)	0
Foreign exchange effect	0		0	0	0
Other investments, ending balance	0	12,916	49,000	0	49,000
Vitura
Other Investments [Roll Forward]
Other investments, beginning balance	6,842	9,601	13,833	9,601	21,993
Unrealized gain (loss)	(3,755)		5,194	(6,097)	(2,729)
Impairment charges	0		0	0	0
Foreign exchange effect	81		(102)	(336)	(339)
Other investments, ending balance	$ 3,168	$ 6,842	$ 18,925	$ 3,168	$ 18,925

Loans Receivable, net - Schedul

Loans Receivable, net - Schedule of Loan Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total current portion of loans receivable, net	$ 4,875	$ 5,541
Total long-term portion of loans receivable, net	73,165	69,036
Total loans receivable, net	78,040	74,577
Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Add: Current portion of accrued interest	0	507
Add: Long-term portion of accrued interest	273	248
Loans Receivable | GrowCo Credit Facility
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current portion of loans receivable, before accrued interest	4,875	5,034
Long term portion of loans receivable, before accrued interest	57,271	53,638
Loans Receivable | Mucci Promissory Note
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	13,929	13,379
Loans Receivable | Cannasoul Collaboration Loan
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	$ 1,692	$ 1,771

Loans Receivable, net - Narrati

Loans Receivable, net - Narrative (Details) ₪ in Thousands, $ in Thousands			1 Months Ended	3 Months Ended				6 Months Ended				12 Months Ended		42 Months Ended	58 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 20, 2024 CAD ($)	Jun. 30, 2024 CAD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 CAD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 CAD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 CAD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 CAD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CAD ($)	Dec. 31, 2022 CAD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 CAD ($)	Jun. 30, 2024 CAD ($)	Jun. 30, 2024 ILS (₪)	Dec. 31, 2023 ILS (₪)	Sep. 30, 2022	Mar. 31, 2022 CAD ($)	Aug. 31, 2021 CAD ($)	Aug. 23, 2019 CAD ($)	Jun. 28, 2019 USD ($)	Jun. 28, 2019 CAD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Draw downs								$ 8,836		$ 0
Proceeds from repayment on loans receivable								$ 5,298		11,388
Decrease in interest receivable	$ 974
Loans Receivable | GrowCo Credit Facility
Accounts, Notes, Loans and Financing Receivable [Line Items]
Face amount																						$ 105,000,000	$ 100,000,000
Face amount increase			$ 70,000,000
Financing receivable term	10 years			10 years				10 years							10 years		10 years	10 years
Draw downs		$ 12,000,000						$ 84,833	$ 116,000,000			$ 78,532	$ 104,000,000
Basis spread on interest rate	1.25%			1.25%				1.25%							1.25%		1.25%	1.25%
Quarterly payment																	$ 1,667,000				$ 1,000,000
Proceeds from repayment on loans receivable				$ 1,216	$ 1,667,000			$ 2,447	3,333,000						$ 10,848	$ 14,833,000
Proceeds from interest on loan receivables				1,401	1,920,000			2,835	3,862,000						17,832	$ 24,384,000
Loans Receivable | Mucci Promissory Note
Accounts, Notes, Loans and Financing Receivable [Line Items]
Face amount																								$ 11,957	$ 16,350,000
Face amount increase	$ 974
Basis spread on interest rate																				1.25%
Proceeds from repayment on loans receivable						$ 1,322	$ 1,750,000			1,322	$ 1,750,000
Proceeds from interest on loan receivables					0	897	1,187,000		0	897	1,187,000			$ 0
Stated interest rate																								3.95%	3.95%
Proceeds from repayment on loan outstanding principal					$ 0	$ 425	$ 563,000		$ 0	$ 425	$ 563,000			$ 0
Loans Receivable | Cannasoul Collaboration Loan | Cannasoul | Establishment of a Commercial Cannabis Analytical Testing Laboratory | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collaborative arrangement, installment received	$ 2,198			$ 2,198				$ 2,198				$ 2,294			$ 2,198			₪ 8,297	₪ 8,297

Loans Receivable, net - Sched_2

Loans Receivable, net - Schedule of Expected Credit Loss Allowances (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	$ 11,347	$ 12,324	$ 11,789	$ 13,066
Increase (decrease)	1,212	(382)	1,021	(1,146)
Foreign exchange effect	(125)	226	(376)	248
Ending balance	12,434	12,168	12,434	12,168
GrowCo Credit Facility | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	10,740	11,719	11,176	12,455
Increase (decrease)	1,207	(379)	1,010	(1,149)
Foreign exchange effect	(109)	239	(348)	273
Ending balance	11,838	11,579	11,838	11,579
Mucci Promissory Note | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	89	91	89	89
Increase (decrease)	1	(7)	3	(5)
Foreign exchange effect	0	2	(2)	2
Ending balance	90	86	90	86
Cannasoul Collaboration Loan | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	518	514	524	522
Increase (decrease)	4	4	8	8
Foreign exchange effect	(16)	(15)	(26)	(27)
Ending balance	$ 506	$ 503	$ 506	$ 503

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 547	$ 0	$ 630	$ 0
Discontinued Operations, Held-for-sale | Cronos Fermentation
Restructuring Cost and Reserve [Line Items]
Loss on write-down of assets			445
Realignment
Restructuring Cost and Reserve [Line Items]
Impairment loss on long-lived assets			1,631
Restructuring costs	$ 547	$ 0	$ 630	$ 0

Restructuring - Restructuring A

Restructuring - Restructuring Activity (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Restructuring Reserve [Roll Forward]
Expenses	$ 547	$ 0	$ 630	$ 0
Realignment
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	38		150
Expenses	547	$ 0	630	$ 0
Payments/Write-offs	(14)		(209)
Accrual, Ending Balance	571		571
Employee termination benefits | Realignment
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	38		150
Expenses	0		62
Payments/Write-offs	(14)		(188)
Accrual, Ending Balance	24		24
Other restructuring costs | Realignment
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	0		0
Expenses	547		568
Payments/Write-offs	0		(21)
Accrual, Ending Balance	$ 547		$ 547

Share-based Compensation - Summ

Share-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 2,236	$ 2,331	$ 4,251	$ 4,866
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	33	372	67	1,106
Restricted share units
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 2,203	$ 1,959	$ 4,184	$ 3,760

Share-based Compensation - Stoc

Share-based Compensation - Stock Options Narrative (Details) - Stock options	6 Months Ended
	Jun. 30, 2024
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	7 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Share-based Compensation - Su_2

Share-based Compensation - Summary of the Changes in Options (Details) - $ / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Weighted average exercise price
Balance at beginning of period (in dollars per share)	$ 14.50	$ 10.57	$ 10.57
Issuance of options (in dollars per share)		2.96
Cancellation, forfeiture and expiry of options (in dollars per share)	19.05	7.75
Balance at end of period (in dollars per share)	5.78	14.50	$ 14.50	$ 10.57
Weighted average exercise price of options exercisable (in dollars per share)	$ 6.59	$ 18.72
Number of options
Balance at beginning of period (in shares)	2,103,201	5,350,600	5,350,600
Issuance of options (in shares)		188,317
Cancellation, forfeiture and expiry of options (in shares)	(1,381,696)	(3,435,716)
Balance at end of period (in shares)	721,505	2,103,201	2,103,201	5,350,600
Exercisable (in shares)	520,820	1,426,612
Weighted-average remaining contractual term (years)
Outstanding	4 years 1 month 17 days	2 years 4 months 2 days	1 year 10 months 2 days	8 months 23 days
Exercisable	3 years 6 months 29 days	1 year

Share-based Compensation - Sche

Share-based Compensation - Schedule of Stock Options Outstanding (Details) - shares	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	721,505	2,103,201	2,103,201	5,350,600
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	702,264	702,264
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	19,241	1,400,937

Share-based Compensation - Su_3

Share-based Compensation - Summary of Changes in RSUs (Details) - Restricted share units - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Weighted-average grant date fair value
Balance at beginning of period (in dollars per share)	$ 3.77	$ 4.63
Granted (in dollars per share)	2.95	2.66
Vested and issued (in dollars per share)	3.53	5.04
Cancellation and forfeitures (in dollars per share)	2.98	3.93
Balance at end of period (in dollars per share)	$ 3.57	$ 3.87
Number of awards
Balance at beginning of period (in shares)	7,381,541	5,725,470
Granted (in shares)	2,503,835	2,819,174
Vested and issued (in shares)	(1,343,425)	(735,523)
Cancellation and forfeitures (in shares)	(91,726)	(254,382)
Balance at end of period (in shares)	8,450,225	7,554,739
Vesting period	3 years
Minimum
Number of awards
Cliff period	3 years
Maximum
Number of awards
Cliff period	5 years

Share-based Compensation - Su_4

Share-based Compensation - Summary of DSU Activity (Details) - Deferred Share Units (DSUs) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Financial liability
Balance at beginning of period	$ 1,092	$ 674
DSU liabilities settled	(359)
Loss (Gain) on revaluation	122	(150)
Balance at end of period	$ 855	$ 524
Number of awards
Balance at beginning of period (in shares)	521,679	265,732
DSU liabilities settled (in shares)	(155,383)
Balance at end of period (in shares)	366,296	265,732

Loss per Share - Schedule of Ea

Loss per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Basic loss per share computation
Net loss from continuing operations attributable to the shareholders of Cronos Group	$ (8,757)	$ (5,526)	$ (10,998)	$ (23,473)
Weighted-average number of common shares outstanding for computation for basic earnings per share (in shares)	382,157,555	380,961,682	381,800,078	380,792,802
Weighted-average number of common shares outstanding for computation for diluted earnings per share (in shares)	382,157,555	380,961,682	381,800,078	380,792,802
Basic loss from continuing operations per share (in dollars per share)	$ (0.02)	$ (0.01)	$ (0.03)	$ (0.06)
Diluted loss per share from continuing operations (in dollars per share)	$ (0.02)	$ (0.01)	$ (0.03)	$ (0.06)
Loss from discontinued operations attributable to the shareholders of Cronos Group	$ 0	$ (2,834)	$ 0	$ (4,056)
Basic loss from discontinued operations per share (in dollars per share)	$ 0	$ (0.01)	$ 0	$ (0.01)
Diluted loss from discontinued operations per share (in dollars per share)	$ 0	$ (0.01)	$ 0	$ (0.01)
Total anti-dilutive securities (in shares)	19,434,059	28,769,758	22,007,363	29,428,093

Commitments and Contingencies (

Commitments and Contingencies (Details) ₪ in Thousands, $ in Thousands	May 16, 2024 ILS (₪)	Apr. 17, 2023 ILS (₪) defendant	Oct. 24, 2022 CAD ($)	Mar. 12, 2020 complaint shareholder
U.S. District Court of Eastern District of New York Vs. Cronos | Pending Litigation
Loss Contingencies [Line Items]
Number of alleged shareholders | shareholder				2
Number of putative class action complaints | complaint				2
OSC Settlement | Settled Litigation
Loss Contingencies [Line Items]
Payments for legal settlements | $			$ 1,340
Green Leaf Vs. Cronos
Loss Contingencies [Line Items]
Number of defendants | defendant		26
Damages sought | ₪		₪ 420,000
Amount awarded to other party | ₪	₪ 10
Green Leaf Vs. Cronos | Cronos Group, Inc.
Loss Contingencies [Line Items]
Number of defendants | defendant		3

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Assets Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 848,189	$ 669,291
Short-term investments		192,237
Other investments	3,168	9,601
Derivative liabilities	21	102
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	848,189	669,291
Short-term investments		192,237
Other investments	3,168	9,601
Derivative liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments		0
Other investments	0	0
Derivative liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments		0
Other investments	0	0
Derivative liabilities	$ 21	$ 102

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Fair Value of Assets Measured on Nonrecurring Basis (Details) (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 14, 2021	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		$ 3,168	$ 19,758	$ 35,251	$ 67,925	$ 62,833	$ 70,993
Sale of stock, price per share (in dollars per share)	$ 0.0001
Sale of stock, percentage of ownership after transaction	10.50%
Purchase of other investments	$ 110,392
PharmaCann
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ownership interest		6.20%		6.60%
PharmaCann
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	473,787
Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		$ 0		$ 25,650
Fair Value, Nonrecurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		0		0
Fair Value, Nonrecurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		0		0
Fair Value, Nonrecurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		$ 0		$ 25,650

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Jun. 20, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Accounts payable		$ 7,840		$ 7,840		$ 12,130
Related Party
Related Party Transaction [Line Items]
Supply agreement, right to purchase percent	80%
Supply agreement, right to purchase forecasted production percent	70%
Supply agreement, right to purchase actual production percent	70%
Supply agreement term	4 years
Cannabis Purchases | Related Party
Related Party Transaction [Line Items]
Purchases		9,942	$ 6,549	16,952	$ 14,015
Accounts payable		1,640		1,640		2,267
Cannabis Germplasm Supply Agreement | Related Party
Related Party Transaction [Line Items]
Amount of transaction		266		627
Manufacturing Services | Related Party
Related Party Transaction [Line Items]
Purchases		260		936
Accounts payable		7		7		11
Manufacturing Services | Immediate Family Member of Management or Principal Owner
Related Party Transaction [Line Items]
Purchases			$ 603		$ 1,436
Accounts payable		$ 0		$ 0		$ 28
Cronos GrowCo
Related Party Transaction [Line Items]
Ownership interest		50%		50%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
Subsequent Events [Abstract]
Acquisition-related costs	$ 196	$ 196